Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou, China.
Ann Thorac Surg. 2010 Aug;90(2):435-42. doi: 10.1016/j.athoracsur.2010.04.002.
The purpose of this study was identify prognostic factors and to investigate the association between postoperative radiotherapy and overall survival of thoracic esophageal squamous cell carcinoma patients.
From January 1993 to March 2007, 1,715 patients underwent extended esophagectomy with three-field lymph node dissection with or without postoperative radiotherapy and were eligible for analysis. Patients were grouped to surgery only (n = 1,277) and surgery plus postoperative radiotherapy (n = 438). Radiation dose was 50 Gy in 25 fractions.
The overall survival rates at 1, 3, 5, and 10 years were 86.6%, 61.3%, 49.4%, and 36.1%, respectively. Univariate and multivariate analyses showed that age 60 years or more, male sex, tumor more than 5 cm long, poorly differentiated histology, T4 tumor, presence of a vascular cancer thrombus in the surgical specimen, lymph node positivity, 3 or more positive lymph nodes, and disease stage II or higher were negative prognostic factors for overall survival. Postoperative radiation therapy improved overall survival for patients with poor disease-related prognostic factors: positive nodal disease, 3 or more positive lymph nodes, stage III/IV, and large or deeply invading tumor. Postoperative radiation had no survival benefit for patients who did not have the poor disease-related prognostic factors.
Postoperative radiotherapy is indicated for patients with poor disease-related prognostic factors.
本研究旨在确定胸段食管鳞癌患者的预后因素,并探讨术后放疗与总生存率的关系。
1993 年 1 月至 2007 年 3 月,1715 例患者接受了三野淋巴结清扫术加或不加术后放疗的扩大食管切除术,符合分析条件。将患者分为单纯手术组(n = 1277)和手术加术后放疗组(n = 438)。放疗剂量为 50Gy/25 次。
1、3、5、10 年的总生存率分别为 86.6%、61.3%、49.4%和 36.1%。单因素和多因素分析显示,年龄 60 岁或以上、男性、肿瘤长度超过 5cm、低分化组织学、T4 肿瘤、手术标本中存在血管癌栓、淋巴结阳性、3 个或更多阳性淋巴结、疾病分期 II 期或更高是总生存率的负预后因素。术后放疗改善了预后不良的疾病相关预后因素患者的总生存率:淋巴结阳性疾病、3 个或更多阳性淋巴结、III/IV 期和大或深部侵犯肿瘤。对于没有不良疾病相关预后因素的患者,术后放疗没有生存获益。
术后放疗适用于预后不良的疾病相关因素患者。